Cargando…
IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
Chronic graft-versus-host disease (cGvHD) remains the most relevant factor affecting survival after allogeneic hematopoietic stem cell transplantation (alloHSCT). Besides corticosteroids (and ibrutinib in the USA), there is no established therapy for cGvHD. Tocilizumab, a humanized IgG1 IL6-receptor...
Autores principales: | Kattner, Anna-Sophia, Holler, Ernst, Holler, Barbara, Klobuch, Sebastian, Weber, Daniela, Martinovic, Danilo, Edinger, Matthias, Herr, Wolfgang, Wolff, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069928/ https://www.ncbi.nlm.nih.gov/pubmed/32086584 http://dx.doi.org/10.1007/s00277-020-03968-w |
Ejemplares similares
-
Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis
por: Wertheimer, Tobias, et al.
Publicado: (2021) -
Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis
por: Fante, Matthias A., et al.
Publicado: (2020) -
Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020) -
Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation
por: Gruber, Isabella, et al.
Publicado: (2022) -
“This Graft-vs.-Host Disease Determines My Life. That's It.”—A Qualitative Analysis of the Experiences and Needs of Allogenic Hematopoietic Stem Cells Transplantation Survivors in Germany
por: Parisek, Mira, et al.
Publicado: (2021)